[Secondary prevention after myocardial infarction].
The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.
Czuriga
István
I
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Kardiológiai Klinika.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D015220:Calcium Channels / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003326:Coronary Circulation / Q000187:drug effects*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004032:Diet; D015444:Exercise; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control* / Q000601:surgery; D009204:Myocardial Revascularization; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D012307:Risk Factors; D055502:Secondary Prevention; D016540:Smoking Cessation; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D015220:Calcium Channels; D002317:Cardiovascular Agents; D000960:Hypolipidemic Agents; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D001241:Aspirin